ClinicalTrials.gg
CompletedNCT00076531Updated Jan 28, 2008

Clinical Trial for Prostate Cancer

A Phase 3 interventional study of Leuprolide Acetate for Injectable Suspension 22.5 mg in Prostate Cancer, sponsored by Oakwood Laboratories, LLC. Completed. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2008-01-28.

Sponsored by Oakwood Laboratories, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
40 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Started
2003
with 3 others
Phase 3
26 of 70
3 open now
Registered
5th of 70
by date
Lead sponsor
2 of 70
Oakwood Laboratories, LLC

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is one of 4 that started in 2003, is one of 26 in phase 3, and was the 5th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Phase III trial using an injectable for treatment of prostate cancer.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Prostate
  • Cancer
  • PSA
  • Leuprolide
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
This record does not list eligibility criteria. Contact the study team before assuming you do or do not qualify.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
None (open label)
06

Study locations

No study locations are listed for this record.

07

References and documents

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2004
First posted
Jan 27, 2004
Start
Dec 2003
Primary completionActual
Nov 2004
Last update
Jan 28, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00076531
Lead sponsor
Oakwood Laboratories, LLC
First posted
Jan 27, 2004
Start date
Dec 2003
Primary completion
Nov 2004
Last update
Jan 28, 2008

Study contacts

James A. Page, M.D.
study chair · Oakwood Laboratories, LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion